OCSL

Business Context and Reporting Period

Oaktree Specialty Lending Corp (OSLE) is a closed-end, externally managed Business Development Company (BDC) regulated under the Investment Company Act of 1940. The company provides customized credit solutions to middle-market companies with limited access to public capital markets. This Form 10-Q covers the quarterly period ended December 31, 2018. As of this date, the company had 140,960,651 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Improvement: The company reported a net increase in net assets of $27.7 million for Q4 2018, a significant turnaround from a net decrease of $30.4 million in Q4 2017. This was driven by a $18.0 million net realized gain (compared to a $0.3 million loss) and a reduction in net unrealized depreciation to $7.0 million (from $43.5 million).
• Investment Income Growth: Total investment income increased 13.0% to $38.3 million, primarily due to a $4.8 million increase in interest income. This was largely attributable to the resumption of Original Issue Discount (OID) accretion on the Dominion Diagnostics loan following the portfolio company's improved performance.
• Expense Management: Net expenses increased slightly to $21.0 million from $20.6 million. This was due to a $3.2 million increase in incentive fees, partially offset by decreases in professional fees and interest expense.
• Liquidity Position: Cash and cash equivalents increased significantly to $56.2 million from $13.4 million, driven by net cash provided by operating activities of $86.9 million.
• Debt Reduction: Total debt outstanding decreased to $612.9 million from $643.4 million, primarily due to $30.0 million in net repayments under the ING Facility.

Outlook, Risks, and Contingencies

• Portfolio Strategy: Management intends to continue rotating the portfolio out of non-core investments (approximately $347 million remaining at fair value) into investments better aligned with Oaktree's credit investing approach, targeting a mix of 40-60% first lien loans and 35-55% second lien loans.
• Asset Coverage: On February 1, 2019, the Board approved the application of reduced asset coverage requirements (150% instead of 200%) effective February 1, 2020, subject to compliance with disclosure requirements. Upon effectiveness, Oaktree intends to reduce the base management fee to 1.0% on assets financed using leverage above 1.0x debt-equity.
• Non-Accrual Status: As of December 31, 2018, seven investments were on cash or PIK non-accrual status, representing 10.69% of the debt portfolio at cost. Notable non-accrual investments include Refac Optical Group, Maverick Healthcare Group, and Cenegenics.
• Legal Proceedings: The company received termination notices regarding an SEC investigation into the Former Adviser (Fifth Street Management LLC). The SEC announced a settlement with Fifth Street Management on December 3, 2018, and the company's obligations regarding the matter are concluded.
• Unfunded Commitments: The company had $104.7 million in unfunded commitments as of December 31, 2018, up from $52.7 million at the end of the prior quarter.

Key Facts for Investor Verification

• Realized Gains Drivers: Verify the specific exit details and proceeds for BeyondTrust Holdings LLC ($12.4M gain), InMotion Entertainment Group ($2.7M gain), and YETI Holdings ($2.7M gain), which comprised the bulk of the $18.0M realized gain.
• Dominion Diagnostics Accretion: Confirm the sustainability of the OID accretion income from Dominion Diagnostics, which significantly boosted Q4 interest income, given the loan's maturity in April 2019.
• Non-Accrual Portfolio Health: Monitor the status of the seven non-accrual investments, particularly Refac Optical Group and Maverick Healthcare, which are under forbearance agreements extending into 2019.
• Fee Waiver Impact: Review the $1.5 million in fees accrued subject to waiver under the contractual fee waiver with Oaktree, including the full waiver of the $1.8 million capital gains incentive fee.
• Debt Maturities: Note the $228.8 million in 2019 Notes maturing on March 1, 2019, and the company's ability to refinance or repay this obligation.